Brief: AB Science: strategy to increase the value of masitinib and to consider NASDAQ listing
28/06/2021 19:08
June 28 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE ANNOUNCED TODAY THAT IT HAS SIGNED AN AGREEMENT
WITH
HISTORICAL SHAREHOLDERS TO IMPLEMENT A JOINT STRATEGY TO
INCREASE VALUE OF MASITINIB
* To study the opportunity of listing AB Science on a
foreign
market, in particular the NASDAQ
* This agreement also includes the signature of a firm
financing
option for an amount of €25 million over the next 12 months, at
the initiative of AB Science
Source text for Eikon: ID:nGNE6WF6jN
Further company coverage: ABS.PA
(Reporting by Sudip Kar-Gupta)
((sudip.kargupta@thomsonreuters.com;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease